Evidence map›Paper›PMID 40247091›Full record

ArticleNPJ precision oncology2025

Benchmarking mouse contamination removing protocols in patient-derived xenografts genomic profiling.

Mukund Bhandari, Funan He, Anna Rogojina, Fuyang Li, Yi Zou, Jing Jiang, Zhao Lai, Peter Houghton, Raushan T Kurmasheva, Yidong Chen and 2 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mukund Bhandari *Greehey Children's Cancer Research Institute, San Antonio, TX, USA.
Funan He *Greehey Children's Cancer Research Institute, San Antonio, TX, USA.
Anna RogojinaGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Fuyang LiGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Yi ZouGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Jing JiangGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Zhao LaiGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Peter HoughtonGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Raushan T KurmashevaGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Yidong ChenGreehey Children's Cancer Research Institute, San Antonio, TX, USA.
Xiaojing WangGreehey Children's Cancer Research Institute, San Antonio, TX, USA. wangx11@uthscsa.edu.
Siyuan ZhengGreehey Children's Cancer Research Institute, San Antonio, TX, USA. zhengs3@uthscsa.edu.

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver CancerU01CA263981 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Raushan Kurmasheva · 2021 to 2026
$3.2M
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain TumorsR01CA258381 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BURMA, SANDEEP · 2021 to 2025
$2.8M
Pediatric Preclinical Testing ConsortiumU01CA199287 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MARIS, JOHN M · 2015 to 2021
$2.1M
Advancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San AntonioR50CA265339 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Zhao Lai · 2022 to 2026
$957k
High Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600k
Illumina NovaSeq 6000 Sequencing SystemS10OD030311 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2021 to 2021
$600k
CPRIT RP220599, RP160716NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA258381NCI NIH HHS R50 CA265339NCI NIH HHS U01 CA199287NCI NIH HHS U01 CA263981NIH HHS S10 OD021805NIH HHS S10 OD030311
6 · The paper itself

Abstract

Patient-derived xenograft (PDX) models are widely used in cancer research. Genomic and transcriptomic profiling of PDXs are inevitably contaminated by sequencing reads originated from mouse cells. Here, we examine the impact of mouse read contamination on RNA sequencing (RNAseq), Whole Exome Sequencing (WES), and Whole Genome Sequencing (WGS) data of 21 PDXs. We also systematically benchmark the performance of 12 computational protocols for removing mouse reads from PDXs. We find that mouse read contamination increases expression of immune and stromal related genes, and inflates the number of somatic mutations. However, detection of gene fusions and copy number alterations is minimally affected by mouse read contamination. Using gold standard datasets, we find that pseudo-alignment protocols often demonstrate better prediction performance and computing efficiency. The best performing tool is a relatively new tool Xengsort. Our results emphasize the importance of removing mouse reads from PDXs and the need to adopt new tools in PDX genomic studies.

Identifiers

PMID40247091
PMCPMC12006369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.